The Effect of Processed Tomato Products on CVD Risks
Not Applicable
Completed
- Conditions
- Cardiovascular Disease
- Interventions
- Dietary Supplement: Tomato products
- Registration Number
- NCT00937742
- Lead Sponsor
- Penn State University
- Brief Summary
The primary working hypothesis is that consuming processed tomatoes frequently/daily will favorably improve endothelium and platelet function disease-risk biomarker profiles in adult men and women compared to consuming no or relatively low amounts of processed tomatoes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
men and women (>21 <70 years) nonsmokers, with a body mass index (BMI) ranging of 25 to 35 kg/m2, BP < or = 140/90 mmHg
Exclusion Criteria
- Total cholesterol (TC) is greater than 300 mg/dL;
- Fasting triglyceride is greater than 300 mg/dL;
- LDL cholesterol (LDL-C) is greater than 180 mg/dL;
- Female subjects who are pregnant or lactating;
- Subjects who are actively losing weight or trying to lose weight;
- Subjects with known allergy or intolerance to tomato products;
- taking any medications that would interfere with outcomes of the study, ie. lipid lowering medications, anti-inflammatory drugs, dietary supplements, such as fish oil or evening primrose;
- subjects' with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, uncontrolled hypertension (>=140/90 mm Hg - ok if controlled below this limit with medication), or other systemic diseases;
- subjects with low hematological counts as determined by >or <15% the upper or lower cut-off values of normal established for the lab;
- Smokers. -
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Non-tomato products Tomato products Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
- Primary Outcome Measures
Name Time Method Vascular function Baseline and end of intervention phase (week 6) Platelet and monocyte function/activity Baseline and end of intervention phase (week 6)
- Secondary Outcome Measures
Name Time Method Lipids Baseline and end of intervention phase (week 6) Insulin/Glucose Baseline and end of intervention phase (week 6) Inflammatory Markers Baseline and end of intervention phase (week 6)
Trial Locations
- Locations (1)
Penn State University
🇺🇸University Park, Pennsylvania, United States